Investigational Drug Information for Milademetan
✉ Email this page to a colleague
What is the drug development status for Milademetan?
Milademetan is an investigational drug.
There have been 12 clinical trials for Milademetan.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 14th 2021.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Daiichi Sankyo, Inc., Rain Oncology Inc, and Rain Therapeutics Inc.
There are ten US patents protecting this investigational drug and sixty-four international patents.
Summary for Milademetan
| US Patents | 10 |
| International Patents | 64 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-07-14) |
| Vendors | 27 |
Recent Clinical Trials for Milademetan
| Title | Sponsor | Phase |
|---|---|---|
| Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer | Rain Oncology Inc | Phase 2 |
| Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer | Institut Curie | Phase 2 |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | Rain Oncology Inc | Phase 1/Phase 2 |
Clinical Trial Summary for Milademetan
Top disease conditions for Milademetan
Top clinical trial sponsors for Milademetan
US Patents for Milademetan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Milademetan | ⤷ Sign Up | Crystals of dispiropyrrolidine derivatives | Daiichi Sankyo Company, Limited (Tokyo, JP) | ⤷ Sign Up |
| Milademetan | ⤷ Sign Up | Crystals of dispiropyrrolidine derivatives | Daiichi Sankyo Company, Limited (Tokyo, JP) | ⤷ Sign Up |
| Milademetan | ⤷ Sign Up | Method for treating cancer by combined use | DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Milademetan
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Milademetan | Brazil | BR112015004816 | 2032-09-06 | ⤷ Sign Up |
| Milademetan | Canada | CA2884238 | 2032-09-06 | ⤷ Sign Up |
| Milademetan | China | CN104812757 | 2032-09-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
